Advertisement

Topics

Search Results for "Benzodiazepine Multiple Sclerosis"

09:40 EST 10th December 2016 | BioPortfolio

Matching Channels

ATX-MS-1467 for patients with multiple sclerosis (MS)

ATX-MS-1467 is a novel treatment that was developed with the aim of working with the immune system to treat the underlying cause of disease rather than just treating the symptoms or suppressing the ...

Systemic Sclerosis

Amyotrophic lateral sclerosis ALS

Diffuse mesangial sclerosis

B lymphocyte stimulator BlyS

Treatment of inflammatory and autoimmune diseases such as systemic lupus erythematosus (SLE), rheumatoid arthritis and multiple sclerosis.

Matching News

[Series] Progressive multiple sclerosis: prospects for disease therapy, repair, and restoration of function

Multiple sclerosis is a major cause of neurological disability, which accrues predominantly during progressive forms of the disease. Although development of multifocal inflammatory lesions is the unde...

Predicting the severity of multiple sclerosis

Cells in the immune system of patients with multiple sclerosis behave differently from those of healthy individuals. Researchers at Linköping University in Sweden have exploited this difference to de...

Roche’s New Multiple Sclerosis Drug Set for Early FDA Approval

Roche’s Ocrevus (ocrelizumab) has been granted a priority review by the FDA as a treatment for relapsing multiple sclerosis (RMS) and primary progressive multiple sclerosis (PPMS).

Researchers lay foundation for innovative treatment of multiple sclerosis

Inhibition of the protein kinase CK2 prevents the development of auto-aggressive T cells, say multiple sclerosis researchers. Multiple sclerosis is the most common chronic inflammatory disease of the ...

Phase III efficacy results of investigational medicine OCREVUS® (ocrelizumab) reinforced by exploratory analyses in two forms of multiple sclerosis

Roche announced today new analyses from the three OCREVUS® (ocrelizumab) Phase III studies in relapsing multiple sclerosis (RMS) and primary progressive multiple sclerosis (PPMS) will be presente...

Phase III efficacy results of investigational medicine OCREVUS® (ocrelizumab) reinforced by exploratory analyses in two forms of multiple sclerosis

Roche announced today new analyses from the three OCREVUS® (ocrelizumab) Phase III studies in relapsing multiple sclerosis (RMS) and primary progressive multiple sclerosis (PPMS) will be presented du...

Hippocampal inflammation linked to depressive symptoms in patients with multiple sclerosis

Patients with multiple sclerosis have higher rates of depression than the general population, including people with other life-long disabling diseases. Symptoms of multiple sclerosis arise from an abn...

[Comment] What is the future of proof of concept studies in multiple sclerosis?

Multiple sclerosis is an inflammatory and neurodegenerative, autoimmune CNS disorder that is—at least in the early phase—amenable to treatment with various immunomodulatory drugs.1 The approval of...

Matching PubMed Articles

Corrigendum.

Corrigendum to Ragheb, S et al. (2011). Multiple sclerosis: BAFF and CXCL13 in cerebrospinal fluid Multiple Sclerosis Journal 17(07) 819-829. [DOI: 10.1177/1352458511398887].

Impact of multiple sclerosis on employment and use of job-retention strategies: The situation in France in 2015.

The main objective of this survey of persons with multiple sclerosis was to describe their employment situation. Secondary objectives were to ascertain when and how multiple sclerosis symptoms first i...

Interdependence of oxysterols with cholesterol profiles in multiple sclerosis.

To investigate levels of oxysterols in healthy control (HC) and multiple sclerosis (MS) patients and their interdependence with demographic, clinical characteristics, and cholesterol biomarkers.

Antibodies to the RNA-binding protein hnRNP A1 contribute to neurodegeneration in a model of central nervous system autoimmune inflammatory disease.

Neurodegeneration is believed to be the primary cause of permanent, long-term disability in patients with multiple sclerosis. The cause of neurodegeneration in multiple sclerosis appears to be multifa...

Comparative efficacy of fingolimod vs natalizumab: A French multicenter observational study.

To compare natalizumab and fingolimod on both clinical and MRI outcomes in patients with relapsing-remitting multiple sclerosis (RRMS) from 27 multiple sclerosis centers participating in the French fo...

Search Whole site using Google

Loading
Quick Search
Advertisement
 
Advertisement Advertisement